<p>哈德逊湾资本管理公司在最近向美国证券交易委员会提交的 13F 文件中披露，第二季度将其在 Ionis Pharmaceuticals, Inc.（纳斯达克代码：IONS - 免费报告）中的持股比例降低了 28.6%。该基金在此期间出售了 299,900 股后，持有 750,000 股该公司的股票。截至其最近的 SEC 文件，哈德逊湾资本管理公司持有 Ionis Pharmaceuticals 约 0.47% 的股份，价值 29,632,000 美元。</p>
<p>获取 <strong>Ionis Pharmaceuticals</strong> 的提醒：</p>
<ul>
<li>这 5 只被低估的股票准备突破吗？</li>
</ul>
<p>其他几家机构投资者和对冲基金最近也调整了对 IONS 的持股。T. Rowe Price Investment Management Inc.在第一季度将其在 Ionis Pharmaceuticals 的持股提高了 14.2%。T. Rowe Price Investment Management Inc.目前持有 16,175,533 股该公司的股票，价值 488,016,000 美元，在上个季度又购买了 2,006,334 股。Adage Capital Partners GP L.L.C.在第二季度将其在 Ionis Pharmaceuticals 的持股提高了 253.3%。Adage Capital Partners GP L.L.C.目前持有 3,800,000 股该公司的股票，价值 150,138,000 美元，在上个季度又购买了 2,724,400 股。Geode Capital Management LLC 在第二季度将其在 Ionis Pharmaceuticals 的持股提高了 1.7%。Geode Capital Management LLC 目前持有 2,891,095 股该公司的股票，价值 114,245,000 美元，在上个季度又收购了 48,141 股。BVF Inc. IL 在第一季度购买了 Ionis Pharmaceuticals 的新头寸，价值 57,727,000 美元。最后，Groupama Asset Managment 在第二季度将其在 Ionis Pharmaceuticals 的持股提高了 8.6%。Groupama Asset Managment 目前持有 1,160,957 股该公司的股票，价值 45,869,000 美元，在上个季度又收购了 91,746 股。93.86% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>Ionis Pharmaceuticals 的内部买卖</h2>
<p>在其他消息中，执行副总裁 Richard S. Geary 于 11 月 6 日（星期四）出售了 33,038 股 Ionis Pharmaceuticals 的股票。股票以平均价格 75.72 美元出售，总价值为 2,501,637.36 美元。交易完成后，该执行副总裁持有 59,657 股公司股票，价值 4,517,228.04 美元。这笔交易代表其持股比例减少了 35.64%。该交易已在向证券交易委员会提交的文件中披露，相关文件可在 SEC 网站上查阅。此外，董事 Joseph H. Wender 于 12 月 1 日（星期一）出售了 28,000 股公司的股票。股票以平均价格 80.82 美元出售，总交易额为 2,262,960.00 美元。交易完成后，该董事直接持有 36,035 股公司股票，价值约 2,912,348.70 美元。这笔交易代表其持股比例减少了 43.73%。该销售的披露信息可在 SEC 文件中找到。在过去三个月中，内部人士出售了 504,866 股公司股票，价值 35,744,766 美元。公司内部人士持有 2.60% 的股票。</p>
<h2>Ionis Pharmaceuticals 的价格表现</h2>
<p>纳斯达克 IONS 的股票在周五开盘价为 80.82 美元。该公司的流动比率为 2.79，速动比率为 2.78，债务与股本比率为 0.96。该股票的 50 日简单移动平均为 74.91 美元，200 日简单移动平均为 56.18 美元。Ionis Pharmaceuticals, Inc.的 1 年最低价为 23.95 美元，1 年最高价为 83.61 美元。该公司的市值为 130.9 亿美元，市盈率为-47.82，贝塔值为 0.30。</p>
<p>Ionis Pharmaceuticals（纳斯达克代码：IONS - 获取免费报告）最近在 10 月 29 日（星期三）发布了季度财报。该公司报告季度每股收益（EPS）为-0.80 美元，超出分析师一致预期的-1.15 美元，超出幅度为 0.35 美元。该公司本季度的收入为 1.5672 亿美元，而分析师预期为 1.3175 亿美元。Ionis Pharmaceuticals 的股本回报率为-44.26%，净利润率为-26.45%。该公司本季度的收入较去年同期增长了 17.2%。在去年同期，该公司每股收益为-0.95 美元。分析师预计 Ionis Pharmaceuticals, Inc.在本年度的每股收益将为-3.5 美元。</p>
<h2>华尔街分析师的看法</h2>
<p>一些研究分析师最近对该股票发表了看法。Guggenheim 在 9 月 23 日（星期二）的研究报告中将 Ionis Pharmaceuticals 的目标股价从 90.00 美元上调至 92.00 美元，并给予该公司 “买入” 评级。美国银行在 12 月 9 日（星期二）的研究报告中将 Ionis Pharmaceuticals 的目标股价从 86.00 美元上调至 97.00 美元，并给予该股票 “买入” 评级。摩根士丹利在 10 月 30 日（星期四）的报告中将 Ionis Pharmaceuticals 的目标股价从 90.00 美元上调至 94.00 美元，并给予该公司 “增持” 评级。Needham &amp; Company LLC 在 10 月 30 日（星期四）的报告中将 Ionis Pharmaceuticals 的目标股价从 78.00 美元上调至 90.00 美元，并给予该股票 “买入” 评级。最后，巴克莱在 10 月 30 日（星期四）的研究报告中将 Ionis Pharmaceuticals 的目标股价从 80.00 美元上调至 95.00 美元，并给予该股票 “增持” 评级。一位分析师对该股票给予了强烈买入评级，十七位分析师给予买入评级，三位分析师给予持有评级，一位分析师给予卖出评级。根据 MarketBeat.com 的数据，Ionis Pharmaceuticals 目前的共识评级为 “适度买入”，平均目标股价为 84.85 美元。</p>
<p><strong>查看我们关于 Ionis Pharmaceuticals 的最新报告</strong></p>
<h2>Ionis Pharmaceuticals 公司简介</h2>
<p>（免费报告）</p>
<p>Ionis Pharmaceuticals, Inc. 在美国发现并开发针对 RNA 的治疗药物。该公司为儿童和成人患者提供用于脊髓性肌萎缩症 (SMA) 的 SPINRAZA；TEGSEDI，一种用于治疗由遗传性转甲状腺素淀粉样变引起的多发性神经病的抗病毒注射剂；以及 WAYLIVRA，一种用于治疗家族性乳糜微粒血症 (FCS) 和家族性部分脂肪营养不良的抗病毒药物。</p>
<h2>另见</h2>
<ul>
<li>五只我们认为比 Ionis Pharmaceuticals 更好的股票</li>
<li>投资中的降级是什么意思？</li>
<li>迪士尼与 OpenAI 达成 10 亿美元交易，带来魔力</li>
<li>WallStreetBets 是什么，它们针对哪些股票？</li>
<li>为什么亚马逊可能在几周内成为 300 美元的股票</li>
<li>S&amp;P/TSX 指数是什么？</li>
<li>Adobe 在财报后获得提振：长期前景看涨</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU9OUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU9OUw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Ionis Pharmaceuticals 吗？</h2>
<p>在考虑 Ionis Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Ionis Pharmaceuticals 并不在名单上。</p>
<p>虽然 Ionis Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Ionis制药

普信金融

<p>哈德逊湾资本管理公司在第二季度减少了对 Ionis 制药的持股比例，降幅为 28.6%，目前持有价值 2963 万美元的股份。其他投资者如普信金融和 Adage Capital 则增加了他们的持股。Ionis 报告第三季度收入增长 17.2%，亏损小于预期。分析师们提高了价格目标，古根海姆和美国银行给予了积极的评级</p>

<p>Hudson Bay Capital Management LP lowered its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 28.6% in the second quarter, according to its most recent 13F filing with the SEC. The fund owned 750,000 shares of the company's stock after selling 299,900 shares during the period. Hudson Bay Capital Management LP owned approximately 0.47% of Ionis Pharmaceuticals worth $29,632,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>哈德逊湾资本管理公司在最近向美国证券交易委员会提交的 13F 文件中披露，第二季度将其在 Ionis Pharmaceuticals, Inc.（纳斯达克代码：IONS - 免费报告）中的持股比例降低了 28.6%。该基金在此期间出售了 299,900 股后，持有 750,000 股该公司的股票。截至其最近的 SEC 文件，哈德逊湾资本管理公司持有 Ionis Pharmaceuticals 约 0.47% 的股份，价值 29,632,000 美元。</p>
</div><p>Get <strong>Ionis Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Ionis Pharmaceuticals</strong> 的提醒：</p>
</div><ul>
<li>Are These 5 Undervalued Stocks Ready to Break Out?</li>
</ul>
<div class="lb-trans"><ul>
<li>这 5 只被低估的股票准备突破吗？</li>
</ul>
</div><p>Several other institutional investors and hedge funds have also recently modified their holdings of IONS. T. Rowe Price Investment Management Inc. lifted its holdings in shares of Ionis Pharmaceuticals by 14.2% in the first quarter. T. Rowe Price Investment Management Inc. now owns 16,175,533 shares of the company's stock valued at $488,016,000 after purchasing an additional 2,006,334 shares in the last quarter. Adage Capital Partners GP L.L.C. raised its position in Ionis Pharmaceuticals by 253.3% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 3,800,000 shares of the company's stock valued at $150,138,000 after buying an additional 2,724,400 shares during the last quarter. Geode Capital Management LLC lifted its stake in Ionis Pharmaceuticals by 1.7% during the 2nd quarter. Geode Capital Management LLC now owns 2,891,095 shares of the company's stock valued at $114,245,000 after acquiring an additional 48,141 shares in the last quarter. BVF Inc. IL purchased a new position in Ionis Pharmaceuticals during the 1st quarter worth $57,727,000. Finally, Groupama Asset Managment grew its stake in shares of Ionis Pharmaceuticals by 8.6% in the 2nd quarter. Groupama Asset Managment now owns 1,160,957 shares of the company's stock worth $45,869,000 after acquiring an additional 91,746 shares in the last quarter. 93.86% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他几家机构投资者和对冲基金最近也调整了对 IONS 的持股。T. Rowe Price Investment Management Inc.在第一季度将其在 Ionis Pharmaceuticals 的持股提高了 14.2%。T. Rowe Price Investment Management Inc.目前持有 16,175,533 股该公司的股票，价值 488,016,000 美元，在上个季度又购买了 2,006,334 股。Adage Capital Partners GP L.L.C.在第二季度将其在 Ionis Pharmaceuticals 的持股提高了 253.3%。Adage Capital Partners GP L.L.C.目前持有 3,800,000 股该公司的股票，价值 150,138,000 美元，在上个季度又购买了 2,724,400 股。Geode Capital Management LLC 在第二季度将其在 Ionis Pharmaceuticals 的持股提高了 1.7%。Geode Capital Management LLC 目前持有 2,891,095 股该公司的股票，价值 114,245,000 美元，在上个季度又收购了 48,141 股。BVF Inc. IL 在第一季度购买了 Ionis Pharmaceuticals 的新头寸，价值 57,727,000 美元。最后，Groupama Asset Managment 在第二季度将其在 Ionis Pharmaceuticals 的持股提高了 8.6%。Groupama Asset Managment 目前持有 1,160,957 股该公司的股票，价值 45,869,000 美元，在上个季度又收购了 91,746 股。93.86% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Insider Buying and Selling at Ionis Pharmaceuticals</h2>
<div class="lb-trans"><h2>Ionis Pharmaceuticals 的内部买卖</h2>
</div><p>In other news, EVP Richard S. Geary sold 33,038 shares of Ionis Pharmaceuticals stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $75.72, for a total value of $2,501,637.36. Following the completion of the transaction, the executive vice president owned 59,657 shares in the company, valued at $4,517,228.04. This trade represents a 35.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, Director Joseph H. Wender sold 28,000 shares of the business's stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $80.82, for a total transaction of $2,262,960.00. Following the completion of the sale, the director directly owned 36,035 shares in the company, valued at approximately $2,912,348.70. This trade represents a 43.73% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 504,866 shares of company stock valued at $35,744,766 in the last three months. 2.60% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在其他消息中，执行副总裁 Richard S. Geary 于 11 月 6 日（星期四）出售了 33,038 股 Ionis Pharmaceuticals 的股票。股票以平均价格 75.72 美元出售，总价值为 2,501,637.36 美元。交易完成后，该执行副总裁持有 59,657 股公司股票，价值 4,517,228.04 美元。这笔交易代表其持股比例减少了 35.64%。该交易已在向证券交易委员会提交的文件中披露，相关文件可在 SEC 网站上查阅。此外，董事 Joseph H. Wender 于 12 月 1 日（星期一）出售了 28,000 股公司的股票。股票以平均价格 80.82 美元出售，总交易额为 2,262,960.00 美元。交易完成后，该董事直接持有 36,035 股公司股票，价值约 2,912,348.70 美元。这笔交易代表其持股比例减少了 43.73%。该销售的披露信息可在 SEC 文件中找到。在过去三个月中，内部人士出售了 504,866 股公司股票，价值 35,744,766 美元。公司内部人士持有 2.60% 的股票。</p>
</div><h2>Ionis Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Ionis Pharmaceuticals 的价格表现</h2>
</div><p>Shares of NASDAQ IONS opened at $80.82 on Friday. The company has a current ratio of 2.79, a quick ratio of 2.78 and a debt-to-equity ratio of 0.96. The stock has a fifty day simple moving average of $74.91 and a two-hundred day simple moving average of $56.18. Ionis Pharmaceuticals, Inc. has a 1-year low of $23.95 and a 1-year high of $83.61. The firm has a market cap of $13.09 billion, a price-to-earnings ratio of -47.82 and a beta of 0.30.</p>
<div class="lb-trans"><p>纳斯达克 IONS 的股票在周五开盘价为 80.82 美元。该公司的流动比率为 2.79，速动比率为 2.78，债务与股本比率为 0.96。该股票的 50 日简单移动平均为 74.91 美元，200 日简单移动平均为 56.18 美元。Ionis Pharmaceuticals, Inc.的 1 年最低价为 23.95 美元，1 年最高价为 83.61 美元。该公司的市值为 130.9 亿美元，市盈率为-47.82，贝塔值为 0.30。</p>
</div><p>Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last issued its quarterly earnings results on Wednesday, October 29th. The company reported ($0.80) EPS for the quarter, beating analysts' consensus estimates of ($1.15) by $0.35. The firm had revenue of $156.72 million for the quarter, compared to analysts' expectations of $131.75 million. Ionis Pharmaceuticals had a negative return on equity of 44.26% and a negative net margin of 26.45%.The business's revenue for the quarter was up 17.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.95) EPS. Analysts anticipate that Ionis Pharmaceuticals, Inc. will post -3.5 earnings per share for the current year.</p>
<div class="lb-trans"><p>Ionis Pharmaceuticals（纳斯达克代码：IONS - 获取免费报告）最近在 10 月 29 日（星期三）发布了季度财报。该公司报告季度每股收益（EPS）为-0.80 美元，超出分析师一致预期的-1.15 美元，超出幅度为 0.35 美元。该公司本季度的收入为 1.5672 亿美元，而分析师预期为 1.3175 亿美元。Ionis Pharmaceuticals 的股本回报率为-44.26%，净利润率为-26.45%。该公司本季度的收入较去年同期增长了 17.2%。在去年同期，该公司每股收益为-0.95 美元。分析师预计 Ionis Pharmaceuticals, Inc.在本年度的每股收益将为-3.5 美元。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师的看法</h2>
</div><p>A number of research analysts recently weighed in on the stock. Guggenheim raised their price target on shares of Ionis Pharmaceuticals from $90.00 to $92.00 and gave the company a &#34;buy&#34; rating in a research report on Tuesday, September 23rd. Bank of America lifted their target price on shares of Ionis Pharmaceuticals from $86.00 to $97.00 and gave the stock a &#34;buy&#34; rating in a research report on Tuesday, December 9th. Morgan Stanley upped their target price on Ionis Pharmaceuticals from $90.00 to $94.00 and gave the company an &#34;overweight&#34; rating in a report on Thursday, October 30th. Needham &amp; Company LLC lifted their price target on Ionis Pharmaceuticals from $78.00 to $90.00 and gave the stock a &#34;buy&#34; rating in a report on Thursday, October 30th. Finally, Barclays boosted their price objective on Ionis Pharmaceuticals from $80.00 to $95.00 and gave the stock an &#34;overweight&#34; rating in a research report on Thursday, October 30th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Ionis Pharmaceuticals currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $84.85.</p>
<div class="lb-trans"><p>一些研究分析师最近对该股票发表了看法。Guggenheim 在 9 月 23 日（星期二）的研究报告中将 Ionis Pharmaceuticals 的目标股价从 90.00 美元上调至 92.00 美元，并给予该公司 “买入” 评级。美国银行在 12 月 9 日（星期二）的研究报告中将 Ionis Pharmaceuticals 的目标股价从 86.00 美元上调至 97.00 美元，并给予该股票 “买入” 评级。摩根士丹利在 10 月 30 日（星期四）的报告中将 Ionis Pharmaceuticals 的目标股价从 90.00 美元上调至 94.00 美元，并给予该公司 “增持” 评级。Needham &amp; Company LLC 在 10 月 30 日（星期四）的报告中将 Ionis Pharmaceuticals 的目标股价从 78.00 美元上调至 90.00 美元，并给予该股票 “买入” 评级。最后，巴克莱在 10 月 30 日（星期四）的研究报告中将 Ionis Pharmaceuticals 的目标股价从 80.00 美元上调至 95.00 美元，并给予该股票 “增持” 评级。一位分析师对该股票给予了强烈买入评级，十七位分析师给予买入评级，三位分析师给予持有评级，一位分析师给予卖出评级。根据 MarketBeat.com 的数据，Ionis Pharmaceuticals 目前的共识评级为 “适度买入”，平均目标股价为 84.85 美元。</p>
</div><p><strong>Check Out Our Latest Report on Ionis Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Ionis Pharmaceuticals 的最新报告</strong></p>
</div><h2>Ionis Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Ionis Pharmaceuticals 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.</p>
<div class="lb-trans"><p>Ionis Pharmaceuticals, Inc. 在美国发现并开发针对 RNA 的治疗药物。该公司为儿童和成人患者提供用于脊髓性肌萎缩症 (SMA) 的 SPINRAZA；TEGSEDI，一种用于治疗由遗传性转甲状腺素淀粉样变引起的多发性神经病的抗病毒注射剂；以及 WAYLIVRA，一种用于治疗家族性乳糜微粒血症 (FCS) 和家族性部分脂肪营养不良的抗病毒药物。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Ionis Pharmaceuticals</li>
<li>What Does Downgrade Mean in Investing?</li>
<li>Disney's $1 Billion Deal Brings Its Magic to OpenAI</li>
<li>What Is WallStreetBets and What Stocks Are They Targeting?</li>
<li>Why Amazon Could Be a $300 Stock Within Weeks</li>
<li>What is the S&amp;P/TSX Index?</li>
<li>Adobe Gets Post-Earnings Lift: Long-Term Outlook Favors Upside</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 Ionis Pharmaceuticals 更好的股票</li>
<li>投资中的降级是什么意思？</li>
<li>迪士尼与 OpenAI 达成 10 亿美元交易，带来魔力</li>
<li>WallStreetBets 是什么，它们针对哪些股票？</li>
<li>为什么亚马逊可能在几周内成为 300 美元的股票</li>
<li>S&amp;P/TSX 指数是什么？</li>
<li>Adobe 在财报后获得提振：长期前景看涨</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU9OUw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=IONS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Ionis Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Ionis Pharmaceuticals 吗？</h2>
</div><p>Before you consider Ionis Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Ionis Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ionis Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Ionis Pharmaceuticals 并不在名单上。</p>
</div><p>While Ionis Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Ionis Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Hudson Bay Capital Management LP 持有 Ionis 制药公司价值 2963 万美元的股份